Metal-organic structure and gas-adsorbing material

Abstract

The purpose of the present invention is to provide a novel metal-organic structure and a gas adsorbent comprising the metal-organic structure. A metal organic structure according to one embodiment of the present invention contains zinc (Zn) and at least one ligand selected from the group consisting of 4-methylimidazole (4-MeIm), imidazole (Im), and benzimidazole (BzIm), and when the molar ratio of 4-MeIm: Im: BzIm, i.e., 4-MeIm: Im: BzIm, is defined as x: y: z, the molar ratios in the three-component composition diagram are A: 1: 0: 0), B (0.608: 0.392: 0), C (0.407: 0.441: 0.152), D (0.278: 0.496: 0.226), E (0: 0.388: 0.612), G (0.221: 0.277: 0.502), and H (

Description

Technical Field The present disclosure relates to metal-organic structures and gas adsorbent materials. Background Art In recent years, research on metal organic structures (MOFs) has been actively conducted. Among MOFs, metal organic structures containing zinc and imidazoles, called zeolite-like imidazole structures (ZIFs), are known to be excellent in thermal stability and chemical stability. For example, Non-Patent Document 1 discloses that cag-type Zn(Im)2 exhibits N2 adsorption and desorption characteristics. Prior art literature Non-patent literature Non-patent literature 1: J. Gandara-Loe et al., “New insights into the breathing phenomenon in ZIF-4”, J. Mater. Chem. A, 2019, 7.14552-14558. Summary of the invention Problems to be solved by the invention The cag-type Zn(Im)2 disclosed in Non-Patent Document 1 has a problem that the gas adsorption and desorption properties under low pressure are not high. The object of the present disclosure is to provide a novel metal-organic structure and a gas adsorbent material comprising the metal-organic structure. Means of solving problems The present inventors have conducted intensive research to solve the above problems and have found a novel metal organic structure having a specific composition. In addition, the present inventors have found that the novel metal organic structure can be used as a gas adsorbent, thereby completing the present disclosure. Examples of the present embodiment are as follows.

[0001] A metal organic structure comprising zinc (Zn) and at least one ligand selected from 4-methylimidazole, imidazole and benzimidazole, Hereinafter, 4-methylimidazole is referred to as 4-MeIm, imidazole is referred to as Im, and benzimidazole is referred to as BzIm. When the molar ratio of 4-MeIm, Im and BzIm, i.e., 4-MeIm:Im:BzIm, is set to x:y:z, in the three-component composition diagram, the molar ratio x:y:z is within the region of the polygon having the following points as vertices, and the region includes the boundary line, A(1:0:0), B(0.608:0.392:0), C(0.407:0.441:0.152), D(0.278:0.496:0.226), E(0:0.613:0.387), F(0:0.388:0.612), G(0.221:0.277:0.502), H(0.455:0.117:0.428), I(0.563:0:0.437).

[0002] The metal organic structure as described in [1] has an ACO type topological structure.

[0003] As described in [1], the metal organic structure is In a powder X-ray diffraction measurement using CuKα rays, diffraction peaks appear at least at diffraction angles 2θ of 28.4±0.4°, 30.6±0.4°, and 35.2±0.4°.

[0004] A gas adsorbent comprising the metal organic structure described in [1] or [2]. Effects of the Invention According to the present invention, a novel metal-organic structure and a gas adsorbent containing the metal-organic structure can be provided. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 The 4-MeIm, Im and BzIm constituting the products obtained in the Examples and Comparative Examples are represented by 1 A diagram obtained by plotting the composition determined by H-NMR measurement on a three-component composition diagram. Figure 2 The X-ray diffraction patterns (a) of the products obtained in Examples 1 to 5 and the X-ray diffraction patterns (b) of the products obtained in Examples 6 to 10 are shown. Figure 3 The X-ray diffraction patterns (c) of the products obtained in Examples 11 to 15 and the X-ray diffraction patterns (d) of the products obtained in Examples 16 to 20 are shown. Figure 4 The X-ray diffraction patterns (e) of the products obtained in Comparative Examples 1 to 3 and the X-ray diffraction patterns (f) of the products obtained in Comparative Examples 4 to 7 are shown. Figure 5 X-ray diffraction patterns of the products obtained in Comparative Examples 8 to 12 are shown. Figure 6 The N2 adsorption amount of the products obtained in Examples 1, 4, 11, 15 and 16 and Comparative Examples 7 and 11 at 77K is shown. DETAILED DESCRIPTION The metal organic structure and gas adsorbent of the present embodiment are described in detail below. One embodiment of the present embodiment is a metal organic structure containing zinc (Zn) and at least one ligand selected from 4-methylimidazole (4-MeIm), imidazole (Im) and benzimidazole (BzIm), when the molar ratio of the above 4-MeIm, Im and BzIm is set to x:y:z (4-MeIm:Im:BzIm), the molar ratio x:y:z in the three-component composition diagram is A(1:0:0), B(0.608:0.392:0), C(0.407:0.441:0.152), D(0.278:0.496:0.226), E(0:0.613:0.387), F(0:0.388:0.612), G(0.221:0.277:0.502), H(0.455:0.117:0.428), and I (0.563:0:0.437) In addition, one aspect of the present embodiment is a gas adsorbent including the metal organic structure. (Metal-organic structures) Generally, metal organic structures are also called MOFs, which are materials with porous coordination network structures with high surface area due to the interaction between metals and organic ligands. The metal organic structure of the present embodiment is a metal organic structure containing zinc (Zn) and at least one ligand selected from 4-methylimidazole (4-MeIm), imidazole (Im) and benzimidazole (BzIm), and the molar ratio of the above 4-MeIm, Im and BzIm is within the above specific range. The molar ratio of 4-MeIm, Im and BzIm is located in the area of ​​the polygon with the above 9 points A to I as vertices in the three-component composition diagram (including the boundary line). The metal organic structure is a new substance and has excellent gas adsorption. Therefore, the metal organic structure of the present embodiment can be used as a gas adsorption material. In metal organic structures, zinc usually exists in the form of zinc cations, especially divalent cations (Zn 2+ ) exist in the form of. In addition, in metal organic structures, 4-methylimidazole (4-MeIm), imidazole (Im) and benzimidazole (BzIm) are usually present as monovalent anions (4-MeIm - 、Im - 、BzIm -) exists in the form of. That is, in the present disclosure, the metal organic structure comprising zinc (Zn) and at least one ligand selected from 4-methylimidazole (4-MeIm), imidazole (Im) and benzimidazole (BzIm) can also be interpreted as a metal organic structure comprising a cation of zinc (Zn) and an anionic ligand of at least one imidazole selected from 4-methylimidazole (4-MeIm), imidazole (Im) and benzimidazole (BzIm). In addition, from the viewpoint of gas adsorption, the metal organic structure of the present embodiment is preferably such that when the molar ratio of 4-MeIm, Im and BzIm is x:y:z (4-MeIm:Im:BzIm), the molar ratio x:y:z is within 1:10 in the three-component composition diagram. A(1:0:0), B”(0.655:0.345:0), C"(0.195:0.526:0.279), D”(0:0.535:0.465), E”(0:0.438:0.562), F" (0.161:0.321:0.518), and G" (0.629:0:0.371) The metal-organic structure within the polygonal region with vertices (including points on the boundary line). The metal organic structure of the present embodiment has an ACO type topological structure, which is one of the preferred forms. From the viewpoint of gas adsorption, it is preferred to have an ACO type topology. The metal organic structure having an ACO type topology can be confirmed by, for example, the method described in the examples, i.e., by powder X-ray diffraction measurement. In addition, when the metal organic structure of the present embodiment has an ACO type topological structure, it includes a case where it has only an ACO type topological structure, and a case where it has an ACO type topological structure and other structures, such as an unknown structure described later. The metal organic structure of this embodiment is In the powder X-ray diffraction measurement performed by CuKα rays, the appearance of diffraction peaks at least at diffraction angles (2θ) of 28.4±0.4°, 30.6±0.4° and 35.2±0.4° is one of the preferred modes. In addition, the metal organic structure containing zinc and at least one ligand selected from 4-methylimidazole, imidazole and benzimidazole in which the above diffraction peaks appear is not yet known, and the above diffraction peaks mean an unknown structure. The powder X-ray diffraction measurement can be performed by, for example, the method described in the examples. In addition, in the case where the metal organic structure of the present embodiment has the above-mentioned unknown structure, it includes the case of having only the unknown structure and the case of having the unknown structure and other structures such as the ACO type topology. There is no particular limitation on the method for producing the metal organic structure of the present embodiment. For example, zinc oxide powder, at least one imidazole selected from 4-methylimidazole, imidazole and benzimidazole, hard balls such as zirconium oxide balls, and solvents added as needed can be added to a ball mill container, and mechanical mixing is performed using a ball mill to synthesize the metal organic structure. As a solvent, for example, N,N-dimethylformamide can be listed. As a specific example of the method for producing the metal organic structure of the present embodiment, the method described in the embodiment can be listed. In this method, the oxygen ions of zinc oxide and the hydrogen ions of imidazoles are separated, and water is obtained as a by-product. After synthesis, the metal organic structure of the present embodiment can be obtained by removing water, solvent, etc. The amount of zinc oxide and imidazoles used as raw materials can be appropriately set with reference to the values ​​of the embodiments described later. (Gas Adsorbent Material) The gas adsorbent of the present embodiment includes the metal organic structure of the present embodiment described above. It is one of the preferred aspects that the gas adsorbent of the present embodiment is the metal organic structure of the present embodiment described above. The gas adsorbent of this embodiment may also contain other components, such as metals such as manganese (Mn), iron (Fe) or cobalt (Co) or organic substances such as 2-methylimidazole (2-MeIm), 4-ethylimidazole (4-EtIm), 2-methylbenzimidazole (2-MeBzIm) or 5-methylbenzimidazole (5-MeBzIm). In addition, the metal organic structure may also be supported on other materials. The gas adsorbent of this embodiment can adsorb various gaseous substances, for example, nitrogen and organic substances. Examples of organic substances include methane, ethane, propane, and butane. The gas adsorbent can be used for various purposes. Examples of uses of the gas adsorbent include, for example, a gas adsorption system using the gas adsorbent, a gas separation system using the gas adsorbent, and a gas storage system using the gas adsorbent. [Example] The present embodiment will be described below with reference to examples, but the present disclosure is not limited to these examples. [Reagents] The following reagents were used in Examples and Comparative Examples. Zinc oxide (ZnO): Fujifilm Wako Pure Chemical Industries, Ltd. 0.02μm, Practical Grade 95.0+% 4-Methylimidazole (4-MeIm): Tokyo Chemical Industry Co., Ltd. > 98.0% Imidazole (Im): Tokyo Chemical Industry Co., Ltd. > 98.0% Benzimidazole (BzIm): Tokyo Chemical Industry Co., Ltd. > 98.0% Ethanol (EtOH): Kanto Chemical Co., Ltd. Special Grade 94.8% to 95.8% N,N-dimethylformamide (DMF): Fujifilm Wako Pure Chemical Industries, Ltd. Super dehydrated, for organic synthesis 99.5+% [Example 1] 1.221 g (15 mmol) of zinc oxide, 2.463 g (30 mmol) of 4-methylimidazole, 3 mL of N,N-dimethylformamide, and 50 g of Φ5 mm zirconium oxide balls were added to a 45 mL ball mill container. The ball mill container was placed on a planetary ball mill device and rotated at 700 rpm for 3 hours. The content was recovered from the ball mill container to remove the zirconium oxide balls. 50 mL of ethanol was added to the above content, stirred, and centrifuged at 16000 rpm for 15 minutes to remove the supernatant. The above operation of adding ethanol, centrifuging, and removing the supernatant was repeated 4 times in total. The precipitate recovered by removing the supernatant was dried at 60° C. under reduced pressure overnight to obtain a powder. [Example 2] A powder was obtained in the same manner as in Example 1 except that 2.155 g (26.25 mmol) of 4-methylimidazole and 0.255 g (3.75 mmol) of imidazole were used instead of 2.463 g (30 mmol) of 4-methylimidazole. [Example 3] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.847 g (22.5 mmol) of 4-methylimidazole, 0.255 g (3.75 mmol) of imidazole and 0.443 g (3.75 mmol) of benzimidazole. [Example 4] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.847 g (22.5 mmol) of 4-methylimidazole and 0.886 g (7.5 mmol) of benzimidazole. [Example 5] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.539 g (18.75 mmol) of 4-methylimidazole, 0.511 g (7.5 mmol) of imidazole and 0.443 g (3.75 mmol) of benzimidazole. [Example 6] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.232 g (15 mmol) of 4-methylimidazole, 0.766 g (11.25 mmol) of imidazole and 0.443 g (3.75 mmol) of benzimidazole. [Example 7] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.232 g (15 mmol) of 4-methylimidazole, 0.511 g (7.5 mmol) of imidazole and 0.886 g (7.5 mmol) of benzimidazole. [Example 8] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.924 g (11.25 mmol) of 4-methylimidazole, 1.021 g (15 mmol) of imidazole, and 0.443 g (3.75 mmol) of benzimidazole. [Example 9] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.924 g (11.25 mmol) of 4-methylimidazole, 0.511 g (7.5 mmol) of imidazole and 1.329 g (11.25 mmol) of benzimidazole. [Example 10] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.821 g (10 mmol) of 4-methylimidazole, 0.681 g (10 mmol) of imidazole and 1.181 g (10 mmol) of benzimidazole. [Example 11] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.616 g (7.5 mmol) of 4-methylimidazole, 1.021 g (15 mmol) of imidazole and 0.886 g (7.5 mmol) of benzimidazole. [Example 12] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.616 g (7.5 mmol) of 4-methylimidazole, 0.766 g (11.25 mmol) of imidazole and 1.329 g (11.25 mmol) of benzimidazole. [Example 13] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.308 g (3.75 mmol) of 4-methylimidazole, 0.766 g (11.25 mmol) of imidazole and 1.772 g (15 mmol) of benzimidazole. [Example 14] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.277 g (18.75 mmol) of imidazole and 1.329 g (11.25 mmol) of benzimidazole. [Example 15] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.021 g (15 mmol) of imidazole and 1.772 g (15 mmol) of benzimidazole. [Example 16] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.847 g (22.5 mmol) of 4-methylimidazole and 0.511 g (7.5 mmol) of imidazole. [Example 17] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.539 g (18.75 mmol) of 4-methylimidazole and 0.766 g (11.25 mmol) of imidazole. [Example 18] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.539 g (18.75 mmol) of 4-methylimidazole and 1.329 g (11.25 mmol) of benzimidazole. [Example 19] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.232 g (15 mmol) of 4-methylimidazole, 0.255 g (3.75 mmol) of imidazole and 1.329 g (11.25 mmol) of benzimidazole. [Example 20] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.308 g (3.75 mmol) of 4-methylimidazole, 1.277 g (18.75 mmol) of imidazole and 0.886 g (7.5 mmol) of benzimidazole. [Comparative Example 1] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.232 g (15 mmol) of 4-methylimidazole and 1.772 g (15 mmol) of benzimidazole. [Comparative Example 2] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.616 g (7.5 mmol) of 4-methylimidazole, 0.511 g (7.5 mmol) of imidazole and 1.7726 g (15 mmol) of benzimidazole. [Comparative Example 3] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.766 g (11.25 mmol) of imidazole and 2.215 g (18.75 mmol) of benzimidazole. [Comparative Example 4] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.616 g (7.5 mmol) of 4-methylimidazole, 0.255 g (3.75 mmol) of imidazole and 2.215 g (18.75 mmol) of benzimidazole. [Comparative Example 5] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.616 g (7.5 mmol) of 4-methylimidazole and 2.658 g (22.5 mmol) of benzimidazole. [Comparative Example 6] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.511 g (7.5 mmol) of imidazole and 2.658 g (22.5 mmol) of benzimidazole. [Comparative Example 7] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 3.544 g (30 mmol) of benzimidazole. [Comparative Example 8] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.232 g (15 mmol) of 4-methylimidazole and 1.021 g (15 mmol) of imidazole. [Comparative Example 9] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.616 g (7.5 mmol) of 4-methylimidazole and 1.532 g (22.5 mmol) of imidazole. [Comparative Example 10] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 0.616 g (7.5 mmol) of 4-methylimidazole, 1.277 g (18.75 mmol) of imidazole and 0.443 g (3.75 mmol) of benzimidazole. [Comparative Example 11] A powder was obtained in the same manner as in Example 1 except that 2.042 g (30 mmol) of imidazole was used instead of 2.463 g (30 mmol) of 4-methylimidazole. [Comparative Example 12] A powder was obtained in the same manner as in Example 1 except that 2.463 g (30 mmol) of 4-methylimidazole was changed to 1.532 g (22.5 mmol) of imidazole and 0.886 g (7.5 mmol) of benzimidazole. [Analysis and evaluation of products] ( 1 H-NMR measurement) The powders (products, MOF) obtained in each example and comparative example were decomposed and dissolved in a deuterated solvent, and the solution was measured. 1 The ratio of 4-methylimidazole (4-MeIm), imidazole (Im) and benzimidazole (BzIm) contained in the product was calculated based on the integrated ratio of the H-NMR spectrum. The ratio of each component was calculated based on the total of 4-MeIm, Im and BzIm being 100 mol%. The decomposition conditions and the measuring apparatus are shown below. Decomposition conditions: Decompose the product with 10wt% deuterated sulfuric acid (D2SO4) in deuterated water (D2O) solution ·Measurement device: INOVA300 (Agilent Technologies) (X-ray diffraction measurement) The powders (products, MOFs) obtained in the respective Examples and Comparative Examples were subjected to X-ray diffraction measurement to confirm the crystal structures. The measurement apparatus and measurement conditions are as follows. ·Measurement device: RINT RAPID II (RIGAKU CO., LTD.) ·Measurement conditions: voltage 50V, current 100mA, collimation diameter Sample angle ω5°, X-ray wavelength CuKα rays X-ray diffraction patterns of ACO-type Zn(4-MeIm)2, cag-type Zn(Im)2, and SOD-type Zn(BzIm)2 were simulated and compared with the products. In addition, cag-type Zn(Im)2 is a known substance disclosed under the name of ZIF-4, and SOD-type Zn(BzIm)2 is a known substance disclosed under the name of ZIF-7 (or ZIF-7-I). (N2 adsorption isotherm determination) The products obtained in Examples 1, 4, 11, 15 and 16 and Comparative Examples 7 and 11 were pretreated under the following conditions and then N2 adsorption isotherms were measured. In addition, the N2 adsorption amount when the N2 relative pressure was 0.01% was determined as the N2 adsorption amount. The pretreatment device, pretreatment conditions, measurement device, and measurement conditions are shown below. ·Pretreatment device: BELPREP vacII (Maiko Toro Co., Ltd.) Pretreatment conditions: vacuum degree <10 -2 Pa, 160℃ heating for 6 hours ·Measurement device: BELSORP max (Masutra Co., Ltd.) ·Measurement conditions: N2 adsorption at 77K temperature and N2 relative pressure of 0-99% When the equilibrium judgment time during measurement is long or the liquid nitrogen for cooling is exhausted, the measurement is interrupted. For such a sample, the adsorption isotherm when the N2 relative pressure reaches 100% cannot be measured. The feed compositions (usage amounts) of 4-MeIm, Im and BzIm in each example and comparative example, and the compositions of 4-MeIm, Im and BzIm in each product obtained 1 The compositions (analysis results) obtained by H-NMR measurement and the crystal structures of the products are shown in Tables 1 and 2. Figure 1 The 4-MeIm, Im and BzIm of each product obtained in the examples and comparative examples are plotted in the three-component composition diagram. 1The composition diagram obtained by H-NMR measurement. Figure 1 In the figure, ○ represents ACO type, △ represents unknown structure, ◇ represents cag type, and × represents SOD type. The X-ray diffraction patterns obtained by X-ray diffraction measurement of the products of each embodiment and comparative example are shown in FIG. Figure 2 to Figure 5 In addition, Figure 2 to Figure 5 The results of X-ray diffraction pattern simulations for ACO-type Zn(4-MeIm)2, cag-type Zn(Im)2, and SOD-type Zn(BzIm)2 are also shown. In addition, the N2 adsorption amounts of the products obtained in Examples 1, 4, 11, 15 and 16 and Comparative Examples 7 and 11 at 77K are shown in FIG. Figure 6 shown. The upper limit and / or lower limit of the numerical range recorded in this specification can be arbitrarily combined to define a preferred range. For example, the upper limit and lower limit of the numerical range can be arbitrarily combined to define a preferred range, the upper limits of the numerical range can be arbitrarily combined to define a preferred range, and the lower limits of the numerical range can be arbitrarily combined to define a preferred range. Although the present embodiment has been described in detail above, specific aspects are not limited to these embodiments. That is, design changes can be made within the scope that does not depart from the gist of the present disclosure, and these changes are also included in the scope of the present disclosure.

Claims

1. A metal organic structure comprising zinc (Zn) and at least one ligand selected from 4-methylimidazole, imidazole and benzimidazole, Hereinafter, 4-methylimidazole is referred to as 4-MeIm, imidazole is referred to as Im, and benzimidazole is referred to as BzIm. When the molar ratio of 4-MeIm, Im and BzIm, i.e., 4-MeIm:Im:BzIm, is set to x:y:z, in the three-component composition diagram, the molar ratio x:y:z is within the region of the polygon having the following points as vertices, and the region includes the boundary line, A(1:0:0), B(0.608:0.392:0), C(0.407:0.441:0.152), D(0.278:0.496:0.226), E(0:0.613:0.387), F(0:0.388:0.612), G(0.221:0.277:0.502), H(0.455:0.117:0.428), I(0.563:0:0.437)。 2. The metal-organic structure according to claim 1, having an ACO type topological structure.

3. The metal organic structure according to claim 1, wherein the metal organic structure is In a powder X-ray diffraction measurement using CuKα rays, diffraction peaks appear at least at diffraction angles 2θ of 28.4±0.4°, 30.6±0.4°, and 35.2±0.4°.

4. A gas adsorbent comprising the metal organic structure according to claim 1 or 2.

Images